[成功的BTK抑制剂治疗来自MYD88突变克隆的耐火转化B细胞淋巴瘤]
Atsushi Uehara1, Hidekazu Nishikii1,2, Yasuhito Suehara1,2
1Department of Hematology, University of Tsukuba Hospital.
[Rinsho ketsueki] The Japanese journal of clinical hematology
|February 12, 2025
概括
本案例研究突出了一个患有扩散性大B细胞淋巴瘤 (DLBCL) 的患者,他转变为淋巴细胞淋巴瘤 (LPL) 并复发. 布鲁顿布鲁顿是一个很棒的城市.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 神经学 神经学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种侵略性的非霍奇金淋巴瘤.
- 淋巴细胞性淋巴瘤 (LPL) 是一种独特的B细胞淋巴瘤,有时与沃尔登斯特罗姆巨型球蛋白血症有关.
- 从LPL转变为DLBCL是一个罕见但已知的现象.
研究的目的:
- 描述了一例罕见的顺序转变和复发的病例,该病例发生在最初被诊断为DLBCL的患者身上.
- 研究布鲁顿的氨酸激酶 (BTK) 抑制剂在管理复杂的B细胞淋巴瘤转化中的潜在作用.
- 突出突变分析在了解疾病进展和指导治疗方面的有用性.
主要方法:
- 病例报告详细介绍了临床过程,治疗干预措施和结果.
- 对初始DLBCL,复发的LPL和随后的DLBCL的组织病理发现的审查.
- 身体突变分析以确定淋巴发育和转变的关键遗传驱动因素.
主要成果:
- 患者经历了R-CHOP的初始缓解,随后作为LPL复发,然后转变回DLBCL与神经参与.
- 救援化疗和随后的提拉布鲁替尼 (一种BTK抑制剂) 治疗导致神经症状改善和自主干细胞移植后的长期缓解.
- 突变分析发现了一种常见的MYD88突变B细胞克隆,是整个疾病过程的基础,这表明了克隆进化模型.
结论:
- 这种情况表明B细胞淋巴瘤的复杂进展,涉及连续的转变和复发.
- 以提拉布鲁替尼为例的BTK抑制剂疗法在治疗转化LPL引起的神经复杂症方面表现有前途.
- 针对BTK可能是MYD88突变B细胞淋巴瘤的可行的治疗策略,其临床过程复杂.
更多相关视频
08:38Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery
Published on: October 4, 2018
21.2K
10:41Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
Published on: March 29, 2017
11.6K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:27Tumor Immunotherapy
464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464